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Portal dosimetry using electronic portal imaging devices (EPIDs) is often applied 
to verify high-energy photon beam treatments. Due to the change in photon energy 
spectrum, the resulting dose values are, however, not very accurate in the case of 
wedged beams if the pixel-to-dose conversion for the situation without wedge is 
used. A possible solution would be to consider a wedged beam as another photon 
beam quality requiring separate beam modeling of the dose calculation algorithm. 
The aim of this study was to investigate a more practical solution: to make aSi 
EPID-based dosimetry models also applicable for wedged beams without an 
extra commissioning effort of the parameters of the model. For this purpose two 
energy-dependent wedge multiplication factors have been introduced to be applied 
for portal images taken with and without a patient/phantom in the beam. These 
wedge multiplication factors were derived from EPID and ionization chamber 
measurements at the EPID level for wedged and nonwedged beams, both with 
and without a polystyrene slab phantom in the beam. This method was verified for 
an EPID dosimetry model used for wedged beams at three photon beam energies 
(6, 10, and 18 MV) by comparing dose values reconstructed in a phantom with 
data provided by a treatment planning system (TPS), as a function of field size, 
depth, and off-axis distance. Generally good agreement, within 2%, was observed 
for depths between dose maximum and 15 cm. Applying the new model to EPID 
dose measurements performed during ten breast cancer patient treatments with 
wedged 6 MV photon beams showed that the average isocenter underdosage of 
5.3% was reduced to 0.4%. Gamma-evaluation (global 3%/3 mm) of these in vivo 
data showed an increase in percentage of points with γ ≤ 1 from 60.2% to 87.4%, 
while γmean reduced from 1.01 to 0.55. It can be concluded that, for wedged beams, 
the multiplication of EPID pixel values with an energy-dependent correction factor 
provides good agreement between dose values determined by an EPID and a TPS, 
indicating the usefulness of such a practical solution.
PACS numbers: 87.55.km, 87.55.kd, 87.55.Qr, 87.56a.ng
Key words: EPID, portal dosimetry, treatment verification, in vivo dosimetry, 
wedged beams
 
I. INTRODUCTION
Electronic portal imaging devices (EPIDs) are widely used for patient positioning. As a result 
of their favorable characteristics, such as a stable dose-response relationship and immediate 
availability of data in digital format, some centers have also chosen EPIDs as their main tool 
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for pretreatment or in vivo dose verification.(1) The number of groups and institutions that use 
EPID dosimetry clinically is increasing and there is a high potential for EPIDs to become a 
routine tool for in vivo dose verification.(2)
Wedges are important beam modifiers utilized in radiotherapy and widely applied routinely, 
and several groups have investigated EPID dosimetry in wedged beams. These studies con-
cerned pretreatment verification of wedged beams by means of portal dosimetry at the EPID 
level,(3-5) verification of the exit dose,(6) determination of the midplane dose at a point(7,8) or 
the midplane 2D dose distribution,(9,10) and the use of EPID dosimetry to determine wedge 
factors.(10,11) Different types of EPIDs, as well as different types of correction procedures, were 
used in these studies. In the model used by Boellaard et al.,(6,9) which was applied in combina-
tion with a liquid-filled matrix ionization chamber EPID, no correction was needed for wedged 
beams. The models that predict CCD camera-based EPID dose images(3-5) required a correction 
for the change in EPID response due to beam hardening introduced by the insertion of a wedge 
in an open beam. For this purpose, Pasma et al.(4) incorporated two functions in their nonwedged 
beam model to take the effects resulting from placing wedges in the beam into account. Nijsten 
et al.(5) introduced in their model an extra factor for wedged fields to correct for the nonlinear 
response of camera-based EPIDs to a different photon energy spectrum. Renner et al.(10) and 
Budgell et al.(11) noted that wedge factors determined with an amorphous silicon (aSi) EPID 
did not agree with those measured with an ionization chamber. Because the aim of the work of 
Budgell and colleagues was to detect only the variation in wedge factors, they did not correct 
the EPID response in wedged beams. However, Renner et al., when observing that their open-
beam algorithm was unable to accurately reproduce the dose from wedged fields for aSi EPIDs, 
proposed to use a heavily filtered beam to determine the parameters required in their model. A 
similar reduction in EPID response was observed by Kirkby and Sloboda(12) when introducing 
a steel compensator in a 6 MV photon beam. These authors proposed to position a 7 mm thick 
copper plate in front of the aSi EPID to reduce the uncertainty in the EPID response when a 
thick absorber is placed in a photon beam. Fidanzio et al.(7) implemented a method for in vivo 
dosimetry of breast tangential irradiation using wedged beams. In that work, the transit signal 
along the central beam axis of 150 and 300 wedged beams was measured with an aSi EPID and 
correlated to the dose at the breast midpoint. Phantom measurements showed that this ratio was 
within the experimental uncertainty of ± 0.5%, the same for the two wedge angles investigated 
in their study. More recently, the method developed by this group was generalized and extended 
to wedged beams supplied by linacs of different manufacturers.(8)
These solutions concern corrections to be applied in wedged beams specific for liquid-filled 
or CCD camera-based types of EPIDs, require elaborate calibration methods for wedged beams 
when using aSi EPIDs, or provide the dose only at a single point in the patient. Several groups 
have developed 2D dosimetry methods using aSi EPIDs for pretreatment verification of open-
beam treatments (i.e., without a wedge and phantom in the beam).(13,14) Other groups have 
developed transit dosimetry models for aSi EPIDs (i.e., for treatments with a patient/phantom in 
the beam).(15-18) Calibration of the EPID in these models is generally performed by converting 
EPID pixel values to dose values using ionization chamber measurements. When introducing a 
wedge in the beam, the fraction of low-energy photons in the beam will change and, therefore, 
will alter the EPID response compared to the situation without wedge. This change in energy 
spectrum is a complicated function of the wedge thickness (i.e., of the off-axis position of a 
specific pixel in the EPID). Correcting for this change in conversion of pixel-to-dose value 
can be done by applying a sophisticated beam calibration model, as for instance proposed by 
Nijsten et al.(19) These authors developed a correction model for aSi EPIDs for differences in 
energy spectrum, which was dependent on off-axis position and patient/phantom thickness. 
Such a modification would require, however, a large number of additional measurements for 
wedged beams. A much easier solution would be to make some simple adjustments for wedged 
beams to an existing open-beam dosimetry model without an extra commissioning effort of the 
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parameters of such a model. The aim of this study was to investigate the accuracy and clinical 
usefulness of such a more practical solution. 
 
II. MATERIALS AND METHODS
A.  EPID dosimetry in beams without wedges
aSi EPIDs (Perkin Elmer RID 1680 AL5 (PerkinElmer, Waltham, MA) /Elekta iViewGT 
Elekta, Crawley, UK)) mounted on SL20i linear accelerators (Elekta) are utilized for all dose 
verification measurements. Photon beam energies of 6, 10, and 18 MV were used in this study. 
The linacs have a motorized internal wedge with a 60° fixed angle. The wedge material is 
cast lead/antimony alloy (96% lead and 4% antimony) with a mass density of 11.1 g/cm3. The 
EPIDs are located at 160 cm distance from the linac focus and have in our institution an addi-
tional 2.5 mm thick copper plate to absorb low-energy photons scattered from the phantom or 
patient.(15,20) Images are acquired using in-house developed software and resampled at 256 × 
256 pixels resulting in an effective pixel size of 1 mm2 in the isocenter plane.(20,21) The aver-
age lifetime of the aSi panels, which are intensively used in our institution, is currently about 
32 months, and is increasing since we stopped using 18 MV photons.
The complete description and assumptions made for our nonwedged beam algorithm for 2D 
and 3D dose reconstruction were presented by Wendling et al.(15,16) In short, the EPID-based, 
back-projection dose reconstruction model takes into account primary dose and a scatter contri-
bution. The latter is computed by convolving a fraction of the former with a single water-based 
kernel. As a consequence, our dose reconstruction model is not applicable for regions with 
tissue heterogeneities, as discussed more extensively by Wendling et al.(15,16) This fraction, 
the normalized scatter-to-primary ratio, is dependent on both depth and lateral position. The 
primary dose in a patient/phantom derived from a certain pixel, ij, in the EPID, Prij, at a point 
at a distance dreconst of the reconstruction plane from the accelerator target is given by:
  (1)
 
where Prij
EPID is the primary dose at the level of the EPID, dEPID is the distance of the EPID 
from the accelerator target, and (dreconst / dEPID)
-2 is the distance correction determined by the 
inverse-square law. The attenuation between the reconstruction plane and the exit surface of 
the patient/phantom is given by the attenuation correction, ACij, and can be derived from the 
radiological path length from the entrance surface to the reconstruction plane, dij
radiol, as follows:
 ACij(dreconst) = T
primary (dij
radiol) / Tprimary (2)
where Tprimary (dij
radiol) is the transmission of the primary dose at dij
radiol and Tprimary the transmis-
sion of the primary dose through the patient/phantom, which is experimentally determined by 
dividing the primary portal dose image PDij
EPID behind the patient/phantom by the corresponding 
“open image” (without the patient/phantom):
 Tprimary = PDij
EPID, with patient / PDij
EPID, without patient (3)
The primary portal dose image behind the patient is measured during the actual patient treat-
ment, while the corresponding open image is measured either just before or after the patient 
treatment. 
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The attenuation correction in an arbitrary plane parallel to the EPID is now obtained by 
adding the exponent dij
radiol / tij
radiol to T primary, in which tij
radiol is the radiological thickness of 
the patient determined at pixel ij. Details of this procedure can be found elsewhere.(15,16)  When 
introducing a wedge in the beam, it is assumed in our new model that, when determining the 
attenuation correction, only T primary has to be corrected because the exponent has the same 
value as for the situation without a wedge.  
If the dose is reconstructed in the radiological midplane, then the attenuation correction can 
in first approximation be written as 1 / √ T primary. The primary dose at the midplane is propor-
tional to PrEPID / √ T primary. When using wedged beams in combination with the calibration of 
the EPID for nonwedged beams, the determination of both PrEPID and T primary will be modified 
due to the change in photon energy spectrum by the insertion of a wedge in the beam. 
B.  EPID dosimetry in beams with wedges
In order to take the change in photon energy spectrum caused by the insertion of a wedge in the 
beam into account, the set of EPID calibration parameters used in our back-projection model 
has to be determined for wedged beams, which would require additional measurements. The 
method we propose in this study is to apply only two correction factors per photon energy, one 
for the portal image with a patient/phantom in the beam and one for the portal image without 
a patient/phantom in the beam, to correct for the effect of the wedge on the EPID dose recon-
struction, while still using the calibration for nonwedged beams. 
The two wedge multiplication factors, wmƒ air and wmƒ ph, are derived for the three beam 
energies from the ratio of the ionization chamber (IC) dose value and the corresponding EPID 
dose value with and without a wedge in the beam, indicated with the subscript w and nw, 
respectively. For this purpose a Semiflex ionization chamber (PTW-Freiburg, Germany) was 
embedded in a PMMA miniphantom (3 cm diameter for 6 and 10 MV, and 4 cm diameter for 
18 MV, and PMMA buildup of 1.5, 2.6, and 3 cm for 6, 10, and 18 MV, respectively), at the 
position of the EPID (SDD = 160 cm) at the center of a 10 × 10 cm2 field. The measurements 
were performed for two collimator angles (90° and 270°). The resulting wmƒ values are now 
given by:
  (4)
 
 
   
  (5)
 
For all phantom irradiations we used the same 20 cm thick (and 30 cm × 30 cm wide) polysty-
rene slab phantom. Data were acquired on two accelerators. 
Elekta accelerators have only one wedge with a 60° wedge angle. Beams with reduced wedge 
angle have contributions with and without this 60° wedge. This is not a problem if the separate 
EPID images from the wedged and nonwedged beam irradiations are available, because then 
only the wedged beam image has to be corrected. However, if only the sum of the two EPID 
images can be analyzed, then a straightforward application of our new method is not possible. 
In order to obtain the correct composite dose for such a situation, the total dose is first recon-
structed from the original total portal image and then multiplied with an appropriate correction 
factor to derive the contribution of the fraction with the wedge in the beam. For this purpose, 
a wedge correction factor, wcf, was introduced, defined as the ratio between the EPID-based 
reconstructed dose at 10 cm depth in a 20 cm thick polystyrene slab phantom, with and with-
out wmƒ corrections to the portal images for a 10 × 10 cm2 60° wedged field. Values for wcƒ 
were derived by averaging over the volume of a sphere with a radius of 0.5 cm centered at the 
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isocenter in the phantom. For irradiations with reduced wedge angle a partial wedge correction 
factor, wcƒpartial, then has to be applied, given by:
    
  (6)
     
in which MUwedge and MUnowedge are the number of wedged and nonwedged beam monitor units, 
respectively; wƒ is the wedge factor, which takes the attenuation of the beam by the wedge into 
account. wƒ is defined as the dose at 10 cm depth inside a phantom for a 10 × 10 cm2 field for 
a wedged beam relative to the dose for a nonwedged beam, for the same number of monitor 
units. Values for wƒ are available from ionization chamber measurements used for commis-
sioning of the TPS. There is a small dependence of wƒ on photon beam energy, and its value 
varies between 0.276 and 0.299. 
The midplane dose is proportional to PrEPID / √ T primary. Therefore, when inserting a wedge 
in the beam, PrEPID has to be corrected by multiplying with wmƒ ph , while T primary has to be 
multiplied with wmƒ ph / wmƒ air yielding an approximate value for the wedge correction factor 
for the total midplane dose:
 wcƒ  ~  √ wmƒ ph . √ wmƒ air (7)
Note that the wedge multiplication factors, wmƒ, are introduced to correct the EPID images 
for a 60° wedge in the beam, while the wedge correction factors, wcƒ, are needed in case of 
irradiations with beams with reduced wedge angle and the separate images of the open and 
wedged beam are not available.
C.   Verification of the dose reconstruction by comparison with predictions from 
the TPS
All dose reconstructions were compared with the predictions from the clinically used TPS 
(Pinnacle 9.2, Philips Medical Systems, Eindhoven, The Netherlands). The TPS dose values 
were calculated using a grid with a voxel size of 2 mm in all dimensions, while the EPID 
pixel pitch of 1 mm in the midplane was downsampled to 2 mm. Previous measurements have 
shown that Pinnacle dose values along the central beam axis of wedged beams agree within 
approximately 1% at depths beyond dose maximum along the central beam axis, and between 
about 1% and 2% off-axis in the high-dose region (data not shown). 
D.  Phantom dose verifications 
The complete description and assumptions made for our nonwedged beam algorithm for 2D 
and 3D dose reconstruction are presented by Wendling et al.(15,16) In these papers it also has 
been described that our method has been checked extensively for many situations including 
various off-axis distances and different isocenter positions with respect to the patient geometry. 
The limitations of our new wedged beam approach were assessed by comparing reconstructed 
dose values with planned dose values at and away from the isocenter — along the central beam 
axis and in the lateral plane through the isocenter. In order to assess the field size dependence 
of wmƒ we used a set of field sizes ranging from 3 × 3 to 23 × 23 cm2 to irradiate the isocentri-
cally aligned polystyrene slab phantom for all three energies. In addition, image acquisition 
of the same fields without a phantom in the beam was performed. The average dose in the 
phantom within a sphere with a radius of 0.5 cm from the isocenter as predicted by our TPS 
was compared with the average dose reconstructed from EPID measurements after converting 
the portal images taken with and without the phantom in the beam with the appropriate wmƒ 
values. For the on-axis comparison, depth dose curves for a 10 × 10 cm2 field size of a wedged 
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beam were derived from the TPS and the EPID reconstructions and compared. Because the 
effect of inserting a wedge in the beam is largest at 6 MV, this comparison was only done at 
this energy. Similarly, for the off-axis region beam profiles from the EPID-based reconstructed 
dose distribution at 10 cm depth were compared with planned profiles, both in the direction 
with and without a wedge gradient. It should be noted that additional measurements using 
different phantom thicknesses may be useful in order to confirm that for treatment sites much 
thicker than 20 cm the new method results also in acceptable agreement with TPS calculations.
 
E.  In vivo dose verifications 
In vivo EPID dose measurements were analyzed for ten breast cancer treatments with wedged 
6 MV beams. These wedged beam treatments were all irradiations of the boost volume, which 
followed whole breast irradiation using an IMRT technique. Most of these wedged fields were 
not tangential but often orthogonal to the boost volume. The thickness of the breast, measured 
along the beam axis through the isocenter, varied for these ten patients between 11.8 and 22.3 cm 
and was on average 16.0 ± 3.2 cm. The depth of the dose reconstruction point varied between 
2.5 and 7.5 cm and was on average 4.0 ± 1.6 cm.
The planned dose data in the plane perpendicular to the beam through the isocenter were 
compared with the dose values reconstructed from the corrected EPID images. The TPS dose 
distribution was calculated using a grid voxel size of 4 mm in all dimensions. The in vivo 
EPID-based reconstructed dose values were corrected by applying the appropriate partial 
wedge correction factors and the resulting dose values were compared with the corresponding 
planned dose data. Details of the verified breast irradiations are shown in Table 1. In this part of 
the study the actual clinical approach was followed, which consists of verifying, in vivo, dose 
distributions in isocenter planes, or planes through the dose prescription point, perpendicular 
to the beam direction, using a 2D γ-evaluation method (global 3%/3 mm criteria) within the 
20% isodose line. The mean γ (γmean) and the 99th percentile of the γ distribution (γ1%, the 
near maximum γ), as well as the percentage of points with γ ≤ 1 (Pγ ≤ 1), were included in the 
analysis. In addition the dose difference at the isocenter or prescription point is reported. For 
the analysis of the data obtained with the wedged beam model, the same four evaluation param-
eters were adopted. If the total dose at the isocenter is deviating more than 3.0%, a warning is 
given (tolerance level exceeded), while for a deviation larger than 5%, an error report is sent 
immediately to a physicist (action level exceeded). These alert criteria are the same for the 
situation with and without wedge.
 
Table 1. Overview of the 6 MV wedged beam breast cancer treatments used for the clinical verification of our method.
  Number Of  Usable Number Of Corresponding
 Patient Number Wedged Beams EPID Images
 1 1 3
 2 1 2
 3 1 3
 4 1 4
 5 2 4
 6 1 2
 7 1 3
 8 2 6
 9 2 6
 10 1 2
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III. RESULTS 
A.  Wedge multiplication factors and wedge correction factors 
The results of the EPID and ionization chamber measurements with and without a 20 cm thick 
polystyrene slab phantom in the beam were used for the determination of the wedge multipli-
cation factors. The resulting wmƒ values are given in Table 2 for the three beam energies for 
the two linacs. The standard deviations were determined from an average over four separate 
measurements, two for both collimator angles (90° and 270°). It is assumed that the precision 
of the nonwedged IC measurements is equal to the precision of the wedged IC measurements 
when averaged over the two collimator angles. 
Table 3 provides values for the wedge correction factors for the three different beam ener-
gies at 10 cm depth in the 20 cm thick slab phantom. The data in the first row are wcƒ values 
obtained by using the two-factor model and the wmƒ data presented in Table 2. The standard 
deviations were derived by propagating the standard deviations given in Table 2 to our formula 
for the primary dose in the midplane. It is assumed here that the total midplane dose has a simi-
lar precision as the primary midplane dose. The second row gives the primary midplane dose 
correction calculated by means of Eq. (7), while the third row displays the total isocenter dose 
correction at the same position, but determined now as the ratio of the dose values calculated 
by the TPS and the dose reconstructed from uncorrected EPID images in 6, 10, and 18 MV 
wedged photon beams within a sphere with a radius 0.5 cm around the isocenter. These values 
were derived by combining the data from the two linacs. The small standard deviations in these 
data are caused by the small differences between corresponding data for the two accelerators. 
The three sets of wedge correction factors are in good agreement.
Table 2. Wedge multiplication factors, wmƒ, and standard deviations (in brackets), derived from EPID and ioniza-
tion chamber measurements performed at two linacs with and without a 20 cm thick polystyrene slab phantom in the 
beam, for three photon beam energies. 
 wmƒ Without the Phantom in the Beam wmƒ With the Phantom in the Beam
 Linac 6 MV 10 MV 18 MV 6 MV 10 MV 18 MV
 A4  1.133 1.028 1.038 1.063 1.030 1.043  (0.014) (0.012) (0.012) (0.017) (0.015) (0.014)
 B1 1.137 1.021 1.038 1.052 1.028 1.047  (0.015) (0.012) (0.012) (0.020) (0.016) (0.016)
 Average 1.135 1.025 1.038 1.058 1.029 1.045  (0.010) (0.009) (0.009) (0.013) (0.011) (0.011)
 
Table 3. Single wedge correction factors, wcƒ, for EPID-based reconstructed dose distributions at 10 cm depth in a 
20 cm thick slab phantom for the three photon beam energies. The first row gives the ratio between reconstructed dose 
values with and without corrections to the portal images obtained during wedged beam irradiations derived using the 
two-factor model and the wmƒ data presented in Table 2. The second row shows values obtained using the approximate 
relationship between wcƒ and wmƒ values using the average data presented in Table 2. The third row shows the ratio 
of a direct comparison of the dose values determined by the TPS and the reconstructed dose values without correc-
tions to the portal images. The dose values have been averaged over the volume of a sphere with a radius of 0.5 cm 
centered at the isocenter.
 Energy 6 MV 10 MV 18 MV
 two-factor model 1.109 1.026 1.041  (0.017) (0.014) (0.014)
 √wmƒ ph . √wmƒ air
 1.096 1.027 1.041
  (0.017) (0.014) (0.014)
 comparison with TPS 1.116 1.024 1.037  (0.012) (0.016) (0.001)
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B.  Phantom dose verifications
The dose values determined by the EPID with and without the multiplication of the pixel values 
in the portal images (with the average wmƒ values from Table 2) were compared with the dose 
values determined by the TPS for the three energies as a function of field size, at 10 cm depth 
in the 20 cm thick polystyrene slab phantom at one of the linacs. EPID dose reconstructions 
from two sets of measurements were averaged. Figure 1 depicts the relative differences between 
EPID-based reconstructed and planned dose values for 6, 10, and 18 MV, respectively. 
This figure shows that the dose values determined by the EPID using the wmƒ values given 
in Table 2 are in good agreement with the data predicted by the TPS. The largest remaining 
difference is seen at 18 MV for a field size of 3 × 3 cm2 (2.1% overdosage with respect to the 
TPS value). 
Depth-dose curves inside a phantom were determined in order to assess the improvement 
for depths other than 10 cm by correcting the portal images from wedged beams. 
Figure 2(a) shows depth-dose curves for a 6 MV 10 × 10 cm2 field, along the central beam 
axis in the 20 cm thick slab phantom for TPS dose values and for EPID-based dose recon-
structions with and without portal image corrections. Figure 2(b) presents the corresponding 
percentage differences between dose values (EPID-TPS) / TPS for a 6 MV 10 × 10 cm2 field. 
From these figures it can be seen that, by multiplying the pixel values in the portal images with 
the wmƒ data given in Table 2, the agreement between the TPS and EPID-based depth-dose 
curves improves considerably at all depths.
In order to verify the dose in the off-axis region, beam profiles along the wedge gradient 
were taken from an EPID-based dose reconstruction for a field size of 10 × 10 cm2 at 10 cm 
depth in the slab phantom, with and without correction of the portal images using the wmƒ 
values from Table 2, and compared with the profiles predicted by our TPS. The reconstructed 
beam profiles in the wedge direction are shown in the top panel of Fig. 3. 
For 6 MV the disagreement between the EPID and TPS profiles is clear, while the disagree-
ment is much smaller for the other energies. The agreement for 6 MV is greatly improved in the 
high-dose region when the wmƒ values are applied, while minor improvements are observed 
in the low-dose region. The comparison between EPID-based and TPS dose profiles in the 
direction perpendicular to the wedge gradient is shown in Fig. 4. Also in this direction better 
agreement can be seen for all energies when applying the wmƒ values and the improvement is 
again the largest for 6 MV. 
 
Fig. 1. Percentage differences between EPID-based dose values from square wedged fields at 10 cm depth in the middle 
of an isocentrically aligned 20 cm thick phantom, determined by the nonwedged (DEPID) and wedged beam approach 
(DEP
corr
ID
ected) and the dose values calculated by the TPS (DTPS), as a function of field size for 6, 10, and 18 MV photon beams. 
Averaging has been done over a sphere with a radius of 0.5 cm around the isocenter. The data have been determined under 
isocentric conditions for 200 MUs. The zero levels for the percentage differences have been indicated by dashed lines.
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(a)      (b) 
 
 
Fig. 2. EPID-based reconstructed depth dose curves (a) using the nonwedged (DEPID) and wedged beam model (DEP
corr
ID
ected), 
for a 10 × 10 cm2 6 MV wedged beam along the central beam axis in a 20 cm thick slab phantom for 200 MUs, compared 
with the data from the TPS (DTPS). Percentage difference (b) between reconstructed and planned dose values as a function 
of depth for the same set of data.
Fig. 3. (Upper panel) Beam profiles along the wedge gradient determined by EPID dose reconstruction using the non-
wedged (DEPID) and wedged beam model (DEP
corr
ID
ected) compared with the data from the TPS (DTPS) for 6, 10, and 18 MV for 
a 10 × 10 cm2 field at 10 cm depth in a 20 cm thick phantom for 200 MUs. (Lower panel) Percentage difference between 
reconstructed and planned dose values for the same set of data.
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C.  In vivo dose verifications
In vivo dose verification was performed for 13 (partially) wedged 6 MV beams for 10 breast 
cancer treatments. Table 4 shows the results of the 2D γ-evaluation including the dose differ-
ence at the isocenter or dose prescription point, for the dose reconstruction with and without 
applying the new wedge model. It can be observed that a considerable improvement in the 
results for all but one beam is obtained when our correction procedure proposed for wedged 
beam irradiations is used. For only one beam with a relatively small wcƒpartial value (beam 1 
of Patient 5) the results are slightly worse. The improvement is most prominent for the fully 
wedged beam applied to Patient 3, which is illustrated by the corresponding change in gamma 
values (see Fig. 5). 
 
Fig. 4. (Upper panel) Beam profiles perpendicular to the wedge gradient determined by EPID dose reconstruction using 
the nonwedged (DEPID) and wedged beam model (DEP
corr
ID
ected) compared with the data from the TPS (DTPS) for 6, 10, and 
18 MV for a 10 × 10 cm2 field at 10 cm depth in a 20 cm thick phantom for 200 MUs. (Lower panel) Percentage difference 
between reconstructed and planned dose values for the same set of data.
Table 4. Results for the dose at the isocenter/dose specification point and the γ-evaluation for the in vivo verification 
of ten breast cancer treatments with 6 MV photon beams using the nonwedged and wedged beam approach. 
 Nonwedged Beam Approach Wedged Beam Approach 
  ΔDisoc     ΔDisoc
 Patient (EPID-     (EPID-
 Number plan) Pγ≤1 % γmean γ1% wcfpartial plan) Pγ≤1 % γmean γ1%
 1 -3.0% 70.2 0.69 1.8 1.024 -0.7% 97.2 0.34 1.1
 2 -5.2% 52.8 1.0 2.2 1.038 -1.6% 95.0 0.47 1.2
 3 -10.9% 49.0 1.4 3.3 1.109 -1.4% 85.0 0.59 3.0
 4 -2.5% 72.5 0.72 1.6 1.024 -0.1% 97.5 0.38 1.2
 5 0.2% 94.5 0.34 1.4 1.024 2.6% 94.5 0.47 1.1
 5 -7.0% 55.7 1.0 2.4 1.061 -1.1% 85.9 0.51 2.2
 6 -3.1% 79.3 0.57 1.7 1.024 -0.8% 98.0 0.32 1.1
 7 -2.2% 87.1 0.57 2.0 1.021 -0.2% 93.1 0.40 1.5
 8 -5.4% 51.9 1.16 2.7 1.068 1.1% 86.3 0.50 1.9
 8 -5.3% 48.7 1.26 2.8 1.069 1.2% 85.1 0.57 2.3
 9 -3.7% 64.1 0.86 2.1 1.056 1.7% 97.5 0.38 1.1
 9 -3.5% 64.3 0.84 2.2 1.051 1.5% 76.9 0.69 2.6
 10 -2.5% 62.7 1.16 5.6 1.046 2.0% 63.9 1.27 7.2
 Weighted -5.3% 60.2 1.01 2.6 1.061 0.4% 87.4 0.55 2.3
 mean (1 SD)a (3.3) (13.5) (0.30) (0.9)  (1.7) (8.9) (0.21) (1.4)
a The weighted mean has been calculated by weighting the EPID dose reconstructions from the individual portal images 
with a weighting factor equal to (wcƒpartial -1).
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It is instructive to average the results from the EPID dose reconstructions from all individual 
portal images corresponding to these 13 beams to assess the overall effect of our method. The 
results from the dose reconstructions were weighted with (wcƒpartial -1) in order to enhance the 
differences for beams having the largest wedge correction. The overall wcƒpartial equals 1.061 
and improves the EPID reconstructed isocenter underdosage with respect to the Pinnacle data 
from 5.3% ± 3.3% to -0.4% ± 1.7%. Also, the improvements of γmean from 1.01 ± 0.30 to 0.55 
± 0.21, and Pγ ≤ 1 from 60.2% ± 13.5% to 87.4% ± 8.9% are compelling.   
 
IV. DISCUSSION
aSi EPID-based dosimetry models, using a nonwedged beam pixel-to-dose conversion, present 
shortcomings in wedged beams, mainly for the lower photon beam energies. The aim of this 
work was to establish a practical wedged beam approach as generic as possible, maintaining 
the simple characteristics of an algorithm using an open-beam calibration. For this purpose, 
two portal image correction factors for wedged beams (wedge multiplication factors) were 
introduced, for the situation with and without a phantom in the beam, each valid for a specific 
energy. This required two additional ionization chamber and EPID measurements, with and 
without a wedge in the beam, for both situations. These wedge multiplication factors can in 
principle be applied in any aSi EPID dosimetry model to convert EPID pixel values into dose 
values when applying nonwedged beams for calibration. Dose reconstruction in a patient/
phantom using portal images corrected in this way showed, for the model applied in our center, 
significant improvements with respect to the uncorrected dose reconstructions, especially for 
6 MV, without the need to have an additional calibration procedure for wedged beams.
The proposed new wedged beam model assumes that these two factors are only dependent 
on beam energy and applicable for all patient/phantom thicknesses, depths, field sizes, and off-
axis distances of clinical interest. This assumption was verified for our model for a number of 
field sizes, which demonstrated that the EPID-based dose values using the wedged beam cor-
rection showed indeed good agreement with the TPS dose values for the three beam energies 
at 10 cm depth in the middle of a 20 cm thick phantom (see Fig. 1). Also the depth-dose curves 
reconstructed from EPID measurements and calculated by the TPS in a 20 cm thick phantom 
for a 10 × 10 cm2 6 MV beam showed good agreement — within 2% for depths between dose 
maximum and about 15 cm depth (see Fig. 2(b)). This conformity is slightly worse compared 
to the accuracy of the depth-dose reconstruction for a nonwedged 10 × 10 cm2 6 MV beam. For 
the 10 × 10 cm2 fields, the lateral dose profiles were also compared for the three beam energies 
                                        (a)                                         (b) 
 
 
 
Fig. 5. γ-evaluation data in a plane through the dose specification point (small white square) showing: (a) verification 
for the fully wedged 6 MV beam of Patient 3 using the nonwedged beam approach; (b) verification with the same portal 
image using the wedged beam approach. The dimension of both images is 25.6 cm × 25.6 cm. The white line indicates 
the intersection of the 20% isodose surface with the plane through the dose specification point perpendicular to the beam.
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at 10 cm depth in a 20 cm thick phantom and showed good agreement with the planned dose 
values (within about 2%). It therefore seems reasonable to assume that the wedge multiplication 
factors measured for 10 × 10 cm2 wedged beams and a 20 cm thick polystyrene slab phantom 
are applicable for a large range of clinically relevant situations. 
A potential source of error in the application of the method described in this paper may exist 
from using a set of model parameters developed for one phantom size on an anatomical region 
of a patient having a different size. For breast cancer treatments using wedged beams, the results 
are good as can be deduced from the data presented in Table 4. However, the values of wmƒ 
as given in Table 2 still have to be determined for much thicker phantom/patient thicknesses 
in order to assess the limitation of the new method in applying these data for other treatment 
sites irradiated with wedged beams. 
Wedge multiplication factors can also be applied in other models to convert aSi EPID pixel 
values into dose values when applying nonwedged beams for calibration. In pretreatment dose 
verification models, comparing measured portal dose images with those predicted by a TPS, as 
for instance those developed by Van Esch et al.(13) and Nicolini et al.,(14) multiplying the EPID 
image measured in a wedged beam with a wmƒ air factor might give good agreement between 
measured and calculated dose values. The same procedure, multiplying the EPID image but now 
with wmƒ ph, can be applied for transit dosimetry models using EPID images measured behind 
phantom/patients (e.g., the models developed by François et al.(17) and Berry et al.(18)) It would 
be interesting to verify if such a simple approach of using a wedge multiplication factor would 
indeed be sufficient to get accurate dose verification for wedged beams using these models.
The data given in Table 2 show that the wmƒ value for the 6 MV beam is smaller with the 
phantom in the beam. This is due to the beam hardening already caused by the phantom, so the 
beam hardening effect of the wedge decreases. For the other two higher energy beams, there is 
within the experimental uncertainty no difference between the two sets of data. Detailed Monte 
Carlo calculations are needed to explain quantitatively the effect of placing a phantom and a 
wedge in the beam on the EPID response for the three photon beam energies, for instance to 
clarify why the wmƒ values for 10 MV are lower than for 18 MV. The data presented in Table 2 
also show that the differences between the wmƒ values for the situation with and without a 
phantom in the beam are small for 10 and 18 MV. Consequently, the transmission of the primary 
dose through the patient/phantom will hardly change when a wedge is inserted in these higher 
energy beams. EPID dosimetry models based on transmission, such as the one used by Berry 
et al.(18) or the one used in our institution, therefore need for higher energies only a correction 
with wmƒ ph of the EPID image measured behind a patient/phantom. Another result of this 
observation is that, when applying in a back-projection model a calculated value for the transmis-
sion instead of a measured value, as proposed by Pecharroman-Gallego et al.,(22) no additional 
correction is needed for higher energy wedged beams. However for 6 MV and probably also 
at lower photon beam energies, the calculated transmission has to be modified with the ratio 
of the two wmƒ values obtained from measurements with and without a phantom in the beam. 
In case a single-factor approach is used for the situation when only the summed EPID image 
of the irradiations with and without wedge in the beam are available, then wcƒpartial has to be 
determined using Eq. (6), which requires knowledge of wcƒ. As can be seen from Table 3, the 
wcƒ values obtained by applying the two-factor model, the approximate formula results, and 
the values obtained by comparison with the TPS, are in good agreement. The small difference 
for the 6 MV beam between the wcƒ values obtained with the two-factor model and the square 
root of the two wmƒ values is caused by an approximation in the scatter contribution to the dose 
involved in deriving Eq. (7). It should be noted that the single-factor approach will probably 
give good results under a number of circumstances, but may do worse at depths further away 
from the midplane. The two-factor approach is more universal and valid for a range of depths, 
and might therefore give more accurate results for more extreme patient thicknesses and field 
sizes, but requires ionization chamber measurements.
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In vivo dose verification of wedged beam treatments using the EPID-based dosimetry model as 
applied in our center, in combination with the proposed wedged beam corrections, demonstrated 
good results both for the dose at the isocenter/dose prescription point and for the γ-evaluation. 
This is in agreement with the data presented in Fig. 1 showing that, for the depths of the dose 
prescription point in these patients (i.e., between 2.5 and 7.5 cm), the difference between the 
reconstructed and predicted dose values is less than 1% when using the new wedged beam 
approach. The results shown in Table 4 confirm that an EPID-based back-projection model 
using the wedged beam approach can be used to accurately verify treatment plans that apply 
wedges even for the most unfavorable situation (i.e., in fully wedged low-energy beams). A 
more extensive clinical validation of our wedged beam model was, however, compromised by 
the lack of EPID images. In our center, in vivo EPID dose verification was introduced simulta-
neously with IMRT, while IMRT gradually rendered wedged beams redundant. In other words, 
in vivo EPID dosimetry and the use of wedges were mutually exclusive in clinical practice. For 
that reason we could only reanalyze a small number of wedged beam irradiations. Also, wcƒ 
and wcƒpartial values are much smaller for wedged 10 and 18 MV beams than for 6 MV beams. 
Hence it would require averaging over many patient measurements to reach the statistical 
significance necessary to surpass the overall uncertainty of EPID-based dose reconstructions 
for these higher energy beams. Since these data were not available, only 6 MV treatments 
were investigated.  
 
V. CONCLUSIONS
The multiplication of pixel values in portal images with two energy-dependent correction fac-
tors, derived from EPID and ionization chamber measurements, to take the change in photon 
energy spectrum by insertion of a wedge in the beam into account, provides good agreement 
between dose values determined by an aSi EPID and a TPS. The results of these phantom 
measurements, as well as those of in vivo dose verifications in wedged beams using the new 
model, indicate that such a practical approach, without an extra commissioning effort, may 
also be used in other models to determine accurately the dose distribution with aSi EPIDs in a 
number of clinical situations of treatments with wedged beams.
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